Even with early and intensive management with the treat-to-target approach, reaching remission is still not achieved in most rheumatoid arthritis (RA) patients, which is one of the driving forces behind the continuous development of novel therapies and the optimization of therapeutic strategies. This article, together with {1,2}, helpfully summarizes advances in antibody engineering and further therapeutic targets such as neuro-immune modulation, gene therapy, and epigenetic modification that are being evaluated in the treatment of RA. This Recommendation is of an article referenced in an F1000 Faculty Review also written by Ladislav Senolt.